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Abstract Didemnin B induces rapid apoptosis in human 
promyeloid HL-60 cells with an optimal concentration of 1 ~VI 
(Grubb et al. (1995) Biochem. Biophys. Res. Commnn. 215, 
1130-1136), but little is known about how it does so. In order to 
determine whether protein tyrosine phosphorylation is involved in 
this rapid induction of apoptosis, HL-60 cells were pre-treated 
with tyrosine kinase inhibitors for 1 h before didemnin B 
treatment. Genistein, 2,5-dihydroxycinnamic acid methyl ester, 
and a range of tyrphostins inhibit didenmin B-induced apoptotic 
morphology in a concentration-dependent manner. DNA frag- 
mentation induced by didemnin B is also inhibited by genistein, 
2.5-dihydroxycinnamic a id methyl ester, and tyrphostins. 
I~y  words: Apoptosis; Didemnin B; Tyrosine 
phosphorylation; Tyrosine kinase inhibitor 
1. Introduction 
signal transduction pathways that are involved in the regula- 
tion of cell growth and differentiation [10]. Previously, tyro- 
sine phoshorylation of proteins has been shown to be involved 
in some types of apoptosis, however, understanding the role 
of such proteins is complicated by the fact that the use of 
specific tyrosine kinase inhibitors has been shown to regulate 
apoptosis both positively and negatively [11,12]. In this study 
a range of tyrosine kinase inhibitors has been used to inves- 
tigate the requirement for protein tyrosine phosphorylation i  
didemnin B-induced apoptosis. 
2. Materials and methods 
2.1. Materials" 
Didemnin B was kindly supplied by UpJohn Laboratories, Kala- 
mazoo, MI, USA. Genistein, 2,5-dihydroxycinnamic acid methyl es- 
ter, and 123 bp DNA ladder were purchased from Sigma, Sydney, 
Australia nd tyrphostins 1,25, B42, B44-, B46, B48, B50+, and B56 
from Calbiochem, San Diego, CA, USA. 
Apoptosis is a form of physiological cell death which ap- 
wars to be under highly complicated regulation, similar to 
ol her cellular processes uch as cell growth and differentiation 
[1 l- Apoptosis can occur through different signalling pathways 
e~ en in a single cell type. Some inducers of apoptosis may 
require a period of days before any apoptotic effect is seen 
~hile others induce apoptosis within only a few hours [2]. 
Didemnin B, a branched cyclic peptolide which is currently 
uader clinical trial as an anticancer agent [3,4], has been 
shown to induce apoptosis in human promyeloid HL-60 cells 
w.ry rapidly. 100% apoptosis is reached after 2-3 h treatment 
ith 1 ~tM didemnin B [5]. The mechanism by which didemnin 
B induces apoptosis is unknown. Studies on the cellular bio- 
chemical effects of didemnin B have shown that it is an in- 
h bitor of protein, DNA, and RNA synthesis, and that it can 
irduce growth arrest in any phase of the cell cycle if used at 
c,,ncentrations of 10 -7 M and above [6]. Immunosuppressive 
a,:tivity has been ascribed to didemnin B similar to that of 
c) closporin A [7], and didemnin B has also been shown to 
suppress phosphorylation of an epidermal cytosolic protein 
(~,100) as does cyclosporin A [8]. However, these effects do 
n~t necessarily explain its ability to induce apoptosis since 
c~ closporin A has been shown not to induce such rapid apop- 
t, ,sis in HL-60 cells (Grubb and Lawen, unpublished). Neither 
is inhibition of protein synthesis likely to be the mechanism of 
irduction since didemnin B induces apoptosis at a concentra- 
tr~n that is much lower than that required to inhibit in vitro 
pote in  synthesis [9]. 
Protein tyrosine phosphorylation is often an early event in 
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2.2. Cell culture 
Human promyeloid HL-60 cells were maintained in RPMI 1640 
medium supplemented with 10% heat-inactivated FCS, 100 U/ml pe- 
nicillin, 100 ~tg/ml streptomycin, 1 mM sodium pyruvate, 2 mM L- 
glutamine, 50 ~tg/ml uridine, and 5 mM Hepes (pH 7.4) at 37°C in the 
presence of 5% CO2. 
2.3. Determination of nuclear morphology 
Treatment of HL-60 cells with didemnin B and tyrosine kinase 
inhibitors was performed at a cell density of about 2 x 105 cells/ml. 
Didemnin B was dissolved in ethanol, and tyrosine kinase inhibitors 
were dissolved in DMSO before dilution in medium. At the end of 
each incubation period, 200 lal aliquots of cells were removed and 
centrifuged onto glass slides coated with 0.01% (w/v) poly-L-lysine 
at 2000 rpm for 5 min in a cytospin. Cells attached to the slides 
were fixed in ethanol/acetic acid (3:1) for 5 min, rinsed in distilled 
water, and then stained with 1 lag/ml 4',6-diamidino-2-phenylin- 
dole. 2HC1 for 5 min. Slides were mounted using anti-fading mount- 
ing medium (10 mg/ml p-phenyldiamine i  90% glycerol, pH 9.0) and 
nuclear morphology was analyzed under UV light (280 nm) through a
Nikon microphot-FX fluorescence microscope. Percentage apoptosis 
was determined by counting at least 400 nuclei from each slide. 
2.4. Analysis of DNA fragmentation 
HL-60 cells were treated with didemnin B and tyrosine kinase in- 
hibitors as described above. To extract cytosolic fragmented DNA, 
2 x 106 cells were lysed after one wash in ice-cold PBS by resuspending 
cells in 100 ~tl lysis buffer (5 mM Tris-HC1 pH 8.0, 20 mM EDTA, 
0.5°/,, Triton X-100). After 10 min on ice, samples were centrifuged for 
15 min at 4°C at 14000xg. SDS and RNAse A were added to the 
supernatant tractions to final concentrations of 1% and 0.2 mg/ml, 
respectively. After 2 h at 56°C, proteinase K was added to a final 
concentration f 0.5 mg/ml and incubated at 37°C for 2 h. DNA was 
precipitated with the addition of 0.1 volume 10 M ammonium acetate 
and 2 vols. cold ethanol at -20°C. Washes in 70% ethanol and 100% 
ethanol were followed by resuspension f the DNA in TBE (45 mM 
Tris-borate, pH 7.4, 1 mM EDTA) plus 7% sucrose. To extract otal 
DNA, 106 cells were resuspended in 50 mM Tris-HC1 pH 7.4, 10 mM 
EDTA, and 100 mM NaCI and incubated for 1 h at 50°C in the 
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Fig. 1. Inhibition of didemnin B-induced apoptosis by genistein. 
The percentage apoptosis induced by 1 gM didemnin B after 1 h 
pretreatment with different genistein concentrations is plotted versus 
time where 0 hours is the time of addition of didemnin B. The gen- 
istein concentrations used were 0 (L©), 25 (I,E2), 50 (A,zx), 75 
(v ,v ) ,  and 100 lag/ml (41',0). The inset shows the controls (open 
symbols) without addition of didemnin B; closed symbols represent 
data from didemnin B-treated incubations. Data represent the mean 
of at least two experiments. For clarity, the standard eviation is in- 
dicated by error bars only for 0 and 100 ~tg/ml genistein of the di- 
demnin B-treated cells. 
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Fig. 2. Inhibition of didemnin B-induced apoptosis by 2,5-dihydrox- 
ycinnamic acid methyl ester. Percentage apoptosis induced by 1 p.M 
didemnin B after 1 h pretreatment with different concentrations of
2,5-dihydroxycinnamic acid methyl ester is plotted versus time where 
0 hours is the time of addition of didemnin B. The 2,5-dihydroxy- 
cinnamic acid methyl ester concentrations used were 0 (O,O), 10 
(1£3), 25 (A, zx ), and 50 ktg/ml (v ,  v). The inset shows the controls 
(open symbols) without addition of didemnin B; closed symbols 
represent data from didemnin B-treated incubations. Data represent 
the mean of at least two experiments. The standard eviation is in- 
dicated by error bars for 0 and 50 ~tg/ml 2,5-dihydroxycinnamic 
acid methyl ester of the didemnin B-treated cells. 
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Fig. 3. Inhibition of didemnin B-induced apoptosis by tyrphostins. 
HL-60 cells were pretreated for 1 h with tyrphostins 1 (A), 25 (B), 
B42 (C), B44- (D), B46 (E), B48 (F), B50+ (G), and B56 (H), and 
percentage apoptosis was determined after a further 3 h incubation 
in the absence (O) or presence (11) of 1 ~tM didemnin B. The data 
represent he mean of at least two experiments with error bars 
showing the standard eviation. 
presence of 0.1% SDS and 200 Ixg/ml proteinase K. After 5 min 
RNAse treatment at 37°C, the DNA was extracted by standard phe- 
nol chloroform procedure and ethanol precipitation. The dry DNA 
pellet was resuspended in distilled water with addition of 7% sucrose. 
The DNA was electrophoresed in a 0.8% agarose gel and then visua- 
lized with a UV transilluminator after staining the gel in 2 Ixg/ml 
ethidium bromide for 10-15 min. 
3. Results  and discussion 
To investigate the possible role of tyrosine phosphorylat ion 
in the pathway of induction of apoptosis by didemnin B, HL- 
60 cells were treated with genistein prior to didemnin B treat- 
ment. Genistein is a tyrosine kinase inhibitor which acts as an 
analogue for the ATP substrate of tyrosine kinases [13]. HL- 
60 cells were pretreated for 1 h with 25, 50, 75, and 100 ~tg/ml 
genistein followed by 1 ~tM didemnin B, and samples were 
taken each hour for 4 h to determine morphological ly the 
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F~g. 4. Effect of tyrosine kinase inhibitors on didemnin B-induced cell morphology. Cells were prepared for fluorescence microscopy as de- 
stribed in section 2. Cells were either treated with the inhibitors alone (left panel) or with inhibitors and didemnin B (right panel). The nuclear 
n orphology of normal (A) and apoptotic (B) HL-60 cells is shown after control treatment (A) and 3 h treatment with 1 pM didemnin B (B). 
( ells were pretreated with 100 Bg/ml genistein (C,D), 25 /ag/ml 2,5-dihydroxycinnamic acid methyl ester (E,F), and 300 pM tyrphostin 1 (G,H) 
f~ r 1 h, and then treated with 1 pM didemnin B (D,F,H) for a further 3 h. 
percentage of apoptosis. Genistein clearly inhibits didemnin 
I~-induced apoptosis in a concentration-dependent manner 
(]:ig. 1). 
Although genistein is considered to be specific for tyrosine 
protein kinases [13], it has been reported to have other non- 
s~ecific effects on cell biochemistry [14]. In order to exclude 
~ay non-specific effects of genistein and to confirm the in- 
volvement of tyrosine kinases we determined whether didem- 
nin B-induced apoptosis could be inhibited by other tyrosine 
kinase inhibitors as well. Therefore, we tested 2,5-dihydroxy- 
c~nnamic acid methyl ester and a range of inhibitors known as 
tyrphostins, which are more specific for tyrosine kinases than 
i~; genistein [15]. 2,5-Dihydroxycinnamic a id methyl ester 
07ig. 2) and the tyrphostins (Fig. 3) prevent didemnin B-in- 
duced apoptosis in a dose-dependent manner. Examples of the 
apoptotic morphology of HL-60 cells after 3 h didemnin B 
treatment with and without pretreatment with the various 
tyrosine kinase inhibitors are given in Fig. 4. The cells pre- 
treated with the inhibitors exhibit nuclear morphologies simi- 
lar to control cells and are thus prevented from undergoing 
apoptosis upon didemnin B treatment. Without inhibitor 
treatment didemnin B induces apoptosis in all cells under 
the conditions used in these experiments (Fig. 4B). 
As an additional proof for apoptosis, DNA laddering was 
examined. HL-60 cells treated with didemnin B with or with- 
out pretreatment with genistein, 2,5-dihydroxycinnamic acid 
methyl ester, tyrphostin 1, and tyrphostin B50+ were lysed, 
and their DNA was subjected to analysis by agarose gel elec- 
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Fig. 5. Effect of tyrosine kinase inhibitors on DNA laddering induced by didemnin B. DNA extracted from HL-60 cells treated with ethanol 
alone as control (lanes 1,7), 1 laM didemnin B for 2 h (lanes 2,8), and 2 h of 1 laM didemnin B after 1 h pretreatment with 100 I.tg/ml genistein 
(lanes 3,9), 25 gg/ml 2,5-dihydroxycinnamic acid methyl ester (lanes 4,10), 300 ktM tyrphostin 1 (lanes 5,11), and 300 laM tyrphostin B50+ 
(lanes 6,12) was separated by gel electrophoresis on a 0.8% agarose gel and stained with ethidium bromide as described in section 2. Lanes 1 
6, fragmented cytosolic DNA extracted from the supernatant after cell lysis; lanes 7-12, crude total DNA indicating similar amounts of chro- 
mosomal DNA in control and inhibitor treated cells. A 123 base pair ladder was used as a standard. 
trophoresis. While cells treated with didemnin B showed a 
DNA ladder of multiples of approx. 200 base pairs, cells pre- 
treated with tyrosine kinase inhibitors howed no such ladder- 
ing pattern (Fig. 5). It is unexpected that tyrphostin 1 would 
inhibit didemnin B-induced apoptosis ince tyrphostin 1 has 
been shown to be ineffective as an inhibitor of the EGF re- 
ceptor kinase [15] and is, therefore, often used as a negative 
control. However there is a large range of tyrosine kinase 
inhibitors, including tyrphostin 1, which inhibit didemnin B- 
induced apoptosis, indicating an involvement of a tyrosine 
kinase. Whether this kinase is an yet unknown (or an yet 
untested for tyrphostin inhibition) or whether the effect of 
tyrphostin 1 is different from tyrosine kinase inhibition has 
yet to be shown. 
Tyrosine phosphorylation has been shown to play a role in 
the induction of apoptosis in other reports, however, the nat- 
ure of the regulation of apoptosis by tyrosine phosphorylation 
is complicated. Tyrosine protein kinase inhibitors have been 
shown to induce apoptosis in HL-60 cells within 18 h [11], and 
our results how that they can inhibit apoptosis in HL-60 cells 
in a much shorter period of treatment. Herbimycin A, another 
tyrosine kinase inhibitor, has been shown to inhibit TNF-and 
dexamethasone-induced apoptosis in U937 cells and rat thy- 
mocytes respectively [12,16]. However, tyrosine phosphoryla- 
tion regulates TNF-and didemnin B-induced apoptosis differ- 
ently. In TNF-induced apoptosis, only the DNA 
fragmentation is prevented by tyrosine kinase inhibition; the 
morphology is still apoptotic, and herbimycin A can be added 
well after commencement of TNF-treatment without losing 
effectiveness [12]. In contrast, in didemnin B-induced apopto- 
sis both apoptotic morphology and DNA fragmentation are 
inhibited by tyrosine kinase inhibition, and we have observed 
that genistein must be added well before didemnin B treat- 
ment for maximal inhibition of apoptosis. Didemnin B-in- 
duced apoptosis is similar to apoptosis induced by ionizing 
radiation which also occurs rapidly and can be inhibited by 
pretreatment with tyrosine kinase inhibitors [17]. It is evident 
that tyrosine phosphorylation is involved in the regulation of 
some apoptotic pathways, including that initiated by didem- 
nin B, however details of these pathways are not yet known. It 
is likely that tyrosine phosphorylation can regulate different 
steps in different regimens of apoptotic ell death. 
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